ViaLase technology could impact glaucoma care for patients worldwide
May 1st, 2022 | 🕒
iSpeech OPT-302 combination therapy with ranibizumab shows BCVA, anatomic improvements in patients with PCV Riad Sherif, CEO of Oculis, gives
May 1st, 2022 | 🕒
iSpeech OPT-302 combination therapy with ranibizumab shows BCVA, anatomic improvements in patients with PCV Riad Sherif, CEO of Oculis, gives
Gloss